Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synaptic proteins in Alzheimer's disease.

Josef Marksteiner1, Walter A Kaufmann, Peter Gurka

  • 1Institute for Biochemical Pharmacology, Department of Psychiatry, University Innsbruck, Austria. j.marksteiner@uibk.ac.at

Journal of Molecular Neuroscience : MN
|April 5, 2002
PubMed
Summary

Chromogranin peptides, including chromogranin A, B, and secretogranin II, are key neuronal markers in the human hippocampus. Their density decreases in Alzheimer

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Live-Cell Imaging of Microglia in Organotypic Brain Slices Using Microcontact Printing.

Biomolecules·2026
Same author

Plasma phospho-tau 217 outperforms plasma phospho-tau 181 analyzed with Lumipulse in detecting Alzheimer's dementia in a real-world memory clinic population.

Frontiers in aging neuroscience·2026
Same author

Resources of Austrian hospital-based departments of neurology and psychiatry for new amyloid-antibody therapies in early Alzheimer dementia : A survey of the Austrian Alzheimer Society.

Wiener klinische Wochenschrift·2025
Same author

Phospho-tau 181 is enhanced in saliva and plasma of edentulous patients: a first sign of dementia?

Frontiers in oral health·2025
Same author

Three-dimensional organotypic mouse brain slices to study Alzheimer's disease pathologies: a review.

Frontiers in dementia·2025
Same author

Catestatin-like immunoreactivity in the skin and related sensory ganglia.

Neuropeptides·2025

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • Chromogranin A, B, and secretogranin II are acidic proteins found in neuronal dense core vesicles.
  • These proteins are integral components of neuronal pathways, particularly in the hippocampus.

Purpose of the Study:

  • To localize chromogranin A, B, and secretogranin II in the human hippocampal formation.
  • To investigate the distribution of these peptides in Alzheimer's disease (AD) compared to controls.
  • To assess the potential of chromogranin peptides as markers for synaptic degeneration in AD.

Main Methods:

  • Immunohistochemistry using antisera against synthetic peptide PE-11 (chromogranin B) and secretoneurin (secretogranin II).
  • Localization of chromogranin A, B, and secretogranin II in human hippocampal sections.

Related Experiment Videos

  • Comparison of peptide distribution in AD patients and control subjects, with analysis of amyloid plaques.

    • Main Results:

    • Chromogranin A, B, and secretogranin II show distinct but overlapping distributions, exclusively in neuronal structures.
    • Chromogranin B exhibited the highest immunoreactivity density, with layer-specific patterns in the dentate gyrus.
    • In AD, 10-20% of amyloid plaques contained chromogranin peptides; secretoneurin and chromogranin B immunoreactivity significantly decreased in several hippocampal subfields and the entorhinal cortex.

    Conclusions:

    • Chromogranin peptides serve as reliable markers for human hippocampal pathways and neuronal structures.
    • These peptides are valuable for studying nerve fibers, especially those terminating in the dentate gyrus inner molecular layer.
    • Chromogranin peptides show potential as neuronal markers for detecting synaptic degeneration in Alzheimer's disease.